Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.67 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.61 |
| ▸ | PGR | P06401 | 1/20 | 0.54 |
| ▸ | TDP2 | O95551 | 1/20 | 0.53 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | PNMT | P11086 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2061739 | 0.90 | KIF11 (0.56) | KIF11SIRT2PGRTDP2CAPN9 | |
| SCHEMBL4897946 | 0.88 | PGR (0.63) | KIF11SIRT2PGRTDP2NPC1 | |
| SCHEMBL30270534 | 0.87 | CA9 (0.56) | KIF11SIRT2PGRTDP2CAPN9 | |
| SCHEMBL495833 | 0.87 | CA9 (0.56) | KIF11SIRT2PGRTDP2CAPN9 | |
| SCHEMBL19954 | 0.85 | PGR (0.71) | KIF11SIRT2PGRTDP2CAPN9 | |
| SCHEMBL28956487 | 0.84 | KIF11 (0.55) | KIF11SIRT2PGRKMT2ACYP3A4 | |
| SCHEMBL16208459 | 0.81 | KIF11 (1.00) | KIF11PGRNPC1LMNAMEN1 | |
| SCHEMBL2616922 | 0.81 | CAPN9 (0.58) | KIF11PGRTDP2CAPN9CASP3 | |
| SCHEMBL31718435 | 0.80 | KIF11 (0.50) | KIF11SIRT2CYP3A4CYP1A2PKM | |
| SCHEMBL6234559 | 0.80 | SIRT2 (0.53) | KIF11SIRT2PGRTDP2CAPN9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025245484-A1 | FOXN1 ACTIVATORS | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4561561-A2 | SUBSTITUTED 3,4-DIHYDROQUINOLINONE INHIBITORS OF TSHR | Septerna, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20250129046-A1 | TETRAHYDROQUINOLINO DERIVATIVES FOR THE TREATMENT OF METASTATIC AND CHEMORESISTANT CANCERS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2025-04-24 | — | — | US | disclosed |
| CN-112638881-B | Tetrahydroquinoline derivatives for the treatment of metastatic and chemotherapy-resistant cancers | 普林斯顿大学托管委员会 | 2025-01-07 | — | — | CN | disclosed |
| US-12162855-B2 | Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2024-12-10 | — | — | US | disclosed |
| CN-119019369-A | Bifunctional molecules comprising an E3 ubiquitin ligase binding moiety linked to a BCL6 targeting moiety | 阿尔维纳斯运营股份有限公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-115397821-B | Bifunctional molecules comprising an E3 ubiquitin ligase binding moiety linked to a BCL6 targeting moiety | 阿尔维纳斯运营股份有限公司 | 2024-09-03 | — | — | CN | disclosed |
| WO-2024026076-A2 | SUBSTITUTED 3,4-DIHYDROQUINOLINONE INHIBITORS OF TSHR | SEPTERNA, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-3554503-B1 | INHIBITORS OF BROMODOMAIN-CONTAINING PROTEIN 4 (BRD4) | UNIV TEXAS (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-0885205-A4 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2002-11-27 | — | — | EP | disclosed |
| EP-1049692-A1 | NOVEL BICYCLENE-SUBSTITUTED OXAZOLIDINONES | Bayer Aktiengesellschaft (DE) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999037641-A1 | NOVEL BICYCLENE-SUBSTITUTED OXAZOLIDINONES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-07-29 | — | — | WO | disclosed |
| EP-0885205-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1998-12-23 | — | — | EP | disclosed |
| US-5780480-A | THROMBOLYTIC AGENTS, ANTICOAGULANTS | MERCK & CO., INC. (US) | 1998-07-14 | — | — | US | disclosed |
| WO-1997031910-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1997-09-04 | — | — | WO | disclosed |
| EP-0275888-B1 | Tricyclic benzimidazoles, process for their preparation and use as medicaments | BOEHRINGER MANNHEIM GMBH (DE) | 1994-04-06 | — | — | EP | disclosed |
| US-5116843-A | Anticoagulants, hypotensive agents and cardiovascular disorder | BOEHRINGER MANNHEIM GMBH (DE) | 1992-05-26 | — | — | US | disclosed |
| US-4954498-A | HYPOTENSIVE AGENTS, ANTICOAGULANTS, CARDIOVASCULAR DISORDERS | BOEHRINGER MANNHEIM GMBH (DE) | 1990-09-04 | — | — | US | disclosed |
| EP-0275888-A2 | Tricyclic benzimidazoles, process for their preparation and use as medicaments | Roche Diagnostics GmbH (DE) | 1988-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | BCL6, BCL6B, BCL3 | KIF11 3728/4885SIRT2 2357/4885PGR 4327/4885 |
| US-20250129046-A1 | TETRAHYDROQUINOLINO DERIVATIVES FOR THE TREATMENT OF METASTATIC AND CHEMORESISTANT CANCERS | ALDH3A1, ALDH1A1, ALDH2 | KIF11 1504/4885SIRT2 726/4885PGR 2855/4885 |
| US-12162855-B2 | Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers | ALDH3A1, ALDH2, ALDH1A1 | KIF11 1184/4885SIRT2 679/4885PGR 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.